Compare MINISO Group Holding Ltd (MNSO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Viatris Inc — how do they compare? MINISO Group Holding Ltd trades at $11.93 (market cap $3.62B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 5.2× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| MNSO | VTRS | |
|---|---|---|
Market Cap | $3.62B | $18.69B |
Sector | Technology | Health |
52-Week High | $26.63 | $17.86 |
52-Week Low | $11.30 | $9.49 |
Enterprise Value | $4.29B | $30.80B |
Dividend Yield | 5.53% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $11.895, down 4.99% in the last session amid a neutral technical outlook. Recent earnings show volatility with a Q1 2026 beat but Q3 and Q4 2025 misses, while fundamentals reveal solid revenue growth to $21.44 billion in 2025 and a net income margin of 8.98%. The company announced a $2 billion share repurchase program in June 2026, signaling confidence.
The stock presents a mixed outlook: valuation ratios like P/E of 12.16 appear reasonable, and analyst consensus is 75% buy, but risks include margin pressure from SG&A growth and competitive retail dynamics. Near-term price action hinges on Q2 2026 earnings delivery against expectations of $0.2754 EPS.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
